Drug-price Transparency for Consumers Act of 2023
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Drug-price Transparency for Consumers Act of 2023 is a House bill introduced in the 118th Congress aimed at increasing transparency around drug pricing to benefit consumers. The bill was referred to the Subcommittee on Health but did not advance further and is currently classified as failed or expired. Specific details about the bill's provisions, including mechanisms for transparency or enforcement, are not available in the provided source data.
This bill sought to enhance drug price transparency for consumers but did not progress beyond early committee referral and has expired without enactment.
- The bill is focused on the health policy area, specifically drug price transparency.
- It was introduced in the House during the 118th Congress and referred to the Subcommittee on Health.
- No official summary or full text is available, limiting detailed analysis of its provisions.
['Consumers seeking clearer information on drug pricing', 'Healthcare providers and payers who may use pricing data', 'Potentially regulatory agencies involved in drug pricing oversight']
['Lack of available text and summary limits understanding of implementation requirements and costs', 'Unclear enforcement mechanisms or authority granted to agencies', 'Potential administrative burden on pharmaceutical companies or healthcare entities if transparency requirements were imposed']
The bill was introduced in the House during the 118th Congress and referred to the Subcommittee on Health but did not advance further. The absence of detailed legislative action or summary information suggests limited progress or prioritization within the legislative agenda during this session.
Hidden impact flags detected: 1
GovScope reviewed 1 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['If enacted, increased drug price transparency could influence pharmaceutical pricing strategies and consumer purchasing behavior.', 'Potential administrative costs for compliance with transparency requirements might affect pharmaceutical companies and healthcare providers.']
The lack of available bill text and official summary hinders thorough public and expert review, which is critical for transparency and informed legislative debate. Monitoring future bills on drug price transparency should prioritize availability of full legislative texts and clear summaries to facilitate oversight.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.